Free Access
Issue
Med Sci (Paris)
Volume 23, Number 11, Novembre 2007
Page(s) 1021 - 1023
Section Nouvelles
DOI https://doi.org/10.1051/medsci/200723111021
Published online 15 November 2007
  1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98 : 10869–74. [Google Scholar]
  2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 : 747–52. [Google Scholar]
  3. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104 : 263–9. [Google Scholar]
  4. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432 : 307–15. [Google Scholar]
  5. Bertheau P, Plassa F, Espie M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360 : 852–4. [Google Scholar]
  6. Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4 : e90. [Google Scholar]
  7. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92 : 3963–7. [Google Scholar]
  8. Moreno CS, Matyunina L, Dickerson EB, et al. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS One 2007; 2 : e441. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.